Literature DB >> 22724414

Platelet function testing in atherothrombotic disease.

Erik Lerkevang Grove1, Robert F Storey, Morten Würtz.   

Abstract

Platelet function testing was introduced more than a century ago with the invention of bleeding time; a test which has now been replaced by more accurate methods. Light transmittance aggregometry is traditionally regarded as the gold standard for evaluating platelet function. However, lately the position of light transmittance aggregometry has been challenged by a panel of new instruments. Aspirin and P2Y12-inhibitors are antiplatelet drugs used for secondary prevention of cardiovascular disease. However, an increasing recognition of the fact that not all patients respond adequately to these agents has prompted a focus on individualising antiplatelet treatment. Platelet function testing enables the detection of patients with high on-treatment platelet reactivity and facilitates individually tailored antiplatelet therapy, yet platelet function tests have still not been adopted into routine clinical practice. The present review outlines key milestones of the development of platelet function testing and provides an up-to-date overview of currently available tests and important studies evaluating their strengths and limitations in a clinical context.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22724414     DOI: 10.2174/138161212803251862

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  6 in total

1.  Association of MicroRNAs and YRNAs With Platelet Function.

Authors:  Dorothee Kaudewitz; Philipp Skroblin; Lukas H Bender; Temo Barwari; Peter Willeit; Raimund Pechlaner; Nicholas P Sunderland; Karin Willeit; Allison C Morton; Paul C Armstrong; Melissa V Chan; Ruifang Lu; Xiaoke Yin; Filipe Gracio; Katarzyna Dudek; Sarah R Langley; Anna Zampetaki; Emanuele de Rinaldis; Shu Ye; Timothy D Warner; Alka Saxena; Stefan Kiechl; Robert F Storey; Manuel Mayr
Journal:  Circ Res       Date:  2015-12-08       Impact factor: 17.367

2.  Genetic determinants of on-aspirin platelet reactivity: focus on the influence of PEAR1.

Authors:  Morten Würtz; Peter H Nissen; Erik Lerkevang Grove; Steen Dalby Kristensen; Anne-Mette Hvas
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

3.  Protocol for a systematic review of the diagnostic and prognostic utility of tests currently available for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular disease.

Authors:  Smriti Raichand; David Moore; Richard D Riley; Marie Lordkipanidzé; Janine Dretzke; Jennifer O'Donnell; Sue Jowett; Sue Bayliss; David A Fitzmaurice
Journal:  Syst Rev       Date:  2013-02-26

4.  Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure.

Authors:  Søs Neergaard-Petersen; Ramzi Ajjan; Anne-Mette Hvas; Katharina Hess; Sanne Bøjet Larsen; Steen Dalby Kristensen; Erik Lerkevang Grove
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

5.  Antiplatelet effects of citalopram in patients with ischaemic stroke: A randomized, placebo-controlled, double-blind study.

Authors:  Kristian Lundsgaard Kraglund; Janne Kaergaard Mortensen; Søren Paaske Johnsen; Grethe Andersen; Erik Lerkevang Grove
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

6.  Evaluation of novel coagulation and platelet function assays in patients with chronic kidney disease.

Authors:  Alyaa Abdelmaguid; Lara N Roberts; Laura Tugores; Jennifer R Joslin; Beverley J Hunt; Kiran Parmar; Danilo Nebres; Salah S Naga; Eman S Khalil; Kate Bramham
Journal:  J Thromb Haemost       Date:  2022-02-03       Impact factor: 16.036

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.